Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service peripheral arterial intervention cases in Texas: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 8% on average (237 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 192 | 24,901 | 44% |
| 2020 | 157 | 24,158 | 47% |
| 2021 | 162 | 22,729 | 51% |
| 2022 | 142 | 19,773 | 54% |
| 2023 | 141 | 18,423 | 57% |
| 2024 | 128 | 16,813 | 59% |
| 2025 from claims | – | 18,118 16,628–19,169 | 59% |
| 2026 forecast | – | 18,427 16,213–21,264 | 60% |
| 2027 forecast | – | 18,724 16,007–22,313 | 60% |
| 2028 forecast | – | 19,023 15,873–23,293 | 61% |
| 2029 forecast | – | 19,324 15,783–24,234 | 61% |
| 2030 forecast | – | 19,627 15,724–25,151 | 62% |
Iliac, femoropopliteal, and tibial angioplasty, stenting, atherectomy. Professional codes (what the surgeon bills): CPT 37220, 37221, 37224, 37225, 37226, 37227, 37228, 37229, 37230, 37231; the hospital bills MS-DRG 252, 253, 254.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 31% of the cases CMS names in Texas; 59 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 21% inpatient hospital, 21% hospital outpatient, 3% surgery center, 55% office. The share outside the hospital has moved +6 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 132 | 20,074−3.1%/yr | −3.1%/yr | 8.5 | 70% | 23,800 in 2030+2.9%/yr |
| Maryland | 52 | 6,992−4.8%/yr | −4.8%/yr | 7.7 | 84% | 8,070 in 2030+2.4%/yr |
| Tennessee | 45 | 5,546−6.3%/yr | −6.3%/yr | 7.5 | 70% | 6,500 in 2030+2.7%/yr |
| North Carolina | 34 | 4,853−8.1%/yr | −8.1%/yr | 4.6 | 39% | 4,620 in 2030−0.8%/yr |
| Virginia | 30 | 3,751−7.6%/yr | −7.6%/yr | 3.5 | 43% | 5,530 in 2030+6.7%/yr |
| Georgia | 21 | 3,651−12%/yr | −12%/yr | 4.0 | 46% | 4,960 in 2030+5.3%/yr |
| Arkansas | 23 | 2,979−1.4%/yr | −1.4%/yr | 7.6 | 45% | 2,520 in 2030−2.8%/yr |
| Louisiana | 12 | 2,691−14%/yr | −14%/yr | 6.3 | 32% | 2,760 in 2030+0.4%/yr |
| South Carolina | 19 | 2,514−4.5%/yr | −4.5%/yr | 3.5 | 25% | 3,310 in 2030+4.7%/yr |
| Oklahoma | 19 | 2,386−5.2%/yr | −5.2%/yr | 4.7 | 47% | 3,400 in 2030+6.1%/yr |
| Mississippi | 27 | 2,361−7.9%/yr | −7.9%/yr | 6.1 | 73% | 2,320 in 2030−0.3%/yr |
| Alabama | 19 | 2,322−11%/yr | −11%/yr | 5.0 | 47% | 2,130 in 2030−1.4%/yr |
| Kentucky | 22 | 2,281−6.3%/yr | −6.3%/yr | 4.7 | 43% | 2,570 in 2030+2%/yr |
| District of Columbia | 10 | 1,226+9.5%/yr | +9.5%/yr | 18.9 | 83% | 1,830 in 2030+6.9%/yr |
| Delaware | 8 | 910−1%/yr | −1%/yr | 5.2 | 79% | 2,020 in 2030+14%/yr |
| West Virginia | 5 | 769−11%/yr | −11%/yr | 3.5 | 0% | 840 in 2030+1.4%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Superficial venous ablation | 220 | 22,416+0.2%/yr | +0.2%/yr | 9.91.9× | 98% | 30,300 in 2030+5.1%/yr |
| Dialysis access | 153 | 14,652−16%/yr | −16%/yr | 7.11.4× | 71% | 14,800 in 2030+0.2%/yr |
| Thrombectomy, IVC filters & venous stents | 30 | 4,117+1.6%/yr | +1.6%/yr | 1.91.1× | 17% | 6,020 in 2030+6.5%/yr |
| Carotid revascularization | 54 | 3,080−4.9%/yr | −4.9%/yr | 1.41.1× | 0% | 3,370 in 2030+1.5%/yr |
| Aortic endografts (EVAR/TEVAR) | 3 | 1,065−5.8%/yr | −5.8%/yr | 0.51.1× | 0% | 1,150 in 2030+1.3%/yr |
Peripheral arterial intervention in every state, and its device makers · Every procedure market in Texas · Every state · Compare with Florida
Medtronic leads with 38% of company spending on these surgeons in 2025, level with 2024.
In 2025, 13 companies reported engagement with Texas’s surgeons worth $192K in consulting, speaking, meals and travel tied to these products, about $1,503 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 58 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.